Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Feb 24;2014(2):CD004707.
doi: 10.1002/14651858.CD004707.pub3.

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia

Karsten Juhl Jørgensen  1 , Peter C Gøtzsche, Christina S Dalbøge, Helle Krogh Johansen
Affiliations
Meta-Analysis

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia

Karsten Juhl Jørgensen et al. Cochrane Database Syst Rev. .

Abstract

Background: Opportunistic fungal infections are a major cause of morbidity and mortality in neutropenic cancer patients and antifungal therapy is used both empirically and therapeutically in these patients.

Objectives: To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia.

Search methods: Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2014, Issue 1 2014), MEDLINE (to January 2014). Letters, abstracts and unpublished trials were accepted. Contact was made with trial authors and industry.

Selection criteria: Randomised clinical trials comparing voriconazole with amphotericin B or fluconazole.

Data collection and analysis: Data on mortality, invasive fungal infection, colonisation, use of additional (escape) antifungal therapy and adverse effects leading to discontinuation of therapy were extracted independently by two review authors.

Main results: Three trials were included. One trial compared voriconazole to liposomal amphotericin B as empirical treatment of fever of unknown origin (suspected fungal infection) in neutropenic cancer patients (849 patients, 58 deaths). The second trial compared voriconazole to amphotericin B deoxycholate in the treatment of confirmed and presumed invasive Aspergillus infections (391 patients, 98 deaths). The third trial compared fluconazole to voriconazole for prophylaxis of fungal infections in patients receiving allogeneic stem cell transplantation (600 patients, number of deaths not stated). In the first trial, voriconazole was significantly inferior to liposomal amphotericin B according to the trial authors' prespecified criteria. More patients died in the voriconazole group and a claimed significant reduction in the number of breakthrough fungal infections disappeared when patients arbitrarily excluded from the analysis by the trial authors were included. In the second trial, the deoxycholate preparation of amphotericin B was used without any indication of the use of premedication to counter side effects and replacement of electrolytes or use of salt water. This choice of comparator resulted in a marked difference in the duration of treatment on the trial drugs (77 days with voriconazole versus 10 days with amphotericin B) and precluded meaningful comparisons of the benefits and harms of the two drugs. The third trial failed to find a difference in fungal free survival or invasive fungal infections at 180 days when voriconazole was compared to fluconazole.

Authors' conclusions: Liposomal amphotericin B is significantly more effective than voriconazole for empirical therapy of fungal infections in neutropenic cancer patients and should be preferred. For treatment of aspergillosis, there are no trials that have compared voriconazole with amphotericin B given under optimal conditions. For prophylactic fungal treatment in patients receiving allogeneic stem cell transplantation, there was no difference between voriconazole and fluconazole regarding fungal free survival or invasive fungal infections.

PubMed Disclaimer

Conflict of interest statement

We certify that we have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (for example employment, consultancy, stock ownership, honoraria, expert testimony).

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Herbrecht 2002 {published and unpublished data}
    1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphothericin B for primary therapy of invasive aspergillosis. The New England Journal of Medicine 2002;347:408-15. - PubMed
Walsh 2002 {published and unpublished data}
    1. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Rafalli J et al. Voriconazole compared with liposomal amphothericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. The New England Journal of Medicine 2002;346:225-34. - PubMed
Wingard 2010 {published data only}
    1. Wingard JR, Carter SL, Walsh TJ et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116:5111-8. - PMC - PubMed

References to studies excluded from this review

Ally 2001 {published data only}
    1. Ally R, Schürmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clinical Infectious Diseases 2001;33:1447-54. - PubMed

References to studies awaiting assessment

Mandhaniya 2011 {published data only}
    1. Mandhaniya S, Swaroop C, Thulkar S, Vishnubhatla S, Kabra SK, Xess I, Bakhshi S. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. Journal of Pediatric Hematology/Oncology December 2011;33(8):e333-41. - PubMed

Additional references

Blot 2002
    1. Blot F, Ede C, Nitenberg GM. Voriconazole versus amphotericin B for invasive aspergillosis. The New England Journal of Medicine 2002;347:2080-1. - PubMed
Edwards 1997
    1. Edwards JE, Bodey GB, Bowden RA, Büchner T, Pauw BE, Filler SG et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clinical Infectious Diseases 1997;25:43-59. - PubMed
Espinel‐Ingroff 2001
    1. Espinel-Ingrof A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. Journal of Clinical Microbiology 2001;39:954-8. - PMC - PubMed
Girmenia 2011
    1. Girmenia C et al. Voriconazole prophylaxis and the risk of invasive fungal infection after allogeneic HCT. (E-letter) Blood 4 Feb, 2011.
Gøtzsche 2002a
    1. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database of Systematic Reviews 2002, Issue 4. Art.No.: CD002003. DOI: 10.1002/14651858.CD002033. [DOI: 10.1002/14651858] - DOI - PubMed
Gøtzsche 2002b
    1. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews 2002, Issue 2. Art.No.: CD000026. DOI: 10.1002/14651858.CD000026. [DOI: 10.1002/14651858] - DOI - PubMed
Hughes 2002
    1. Hughes W, Armstrong D, Bodey G, Bow E, Brown A, Calandra T. Lipid formulations of amphothericin B for empirical treatment of fever and neutropenia (reply). Clinical Infectious Diseases 2002;35:897-8. - PubMed
Imhof 2004
    1. Imhof A, Arunmozhi B, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clinical Infectious Diseases 2004;39:743-6. - PubMed
Johansen 2000
    1. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane Database of Systematic Reviews 2000, Issue 3. Art. No.: CD000969. DOI: 10.1002/14651858.CD000969. [DOI: 10.1002/14651858] - DOI - PubMed
Johansen 2002
    1. Johansen HK, Gøtzsche PC. Amphothericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD000239. DOI: 10.1002/14651858.CD000239. [DOI: 10.1002/14651858] - DOI - PubMed
Karthaus 2002
    1. Karthaus M. Voriconazole versus amphotericin B for invasive aspergillosis. The New England Journal of Medicine 2002;347:2080-1. - PubMed
Pearson 2003
    1. Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: A new triazole antifungal agent. The Annals of Pharmacotherapy 2003;37:420-32. - PubMed
Powers 2002
    1. Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. The New England Journal of Medicine 2002;346:289-90. - PubMed
Richardson 1998
    1. Richardson MD, Kokki MH. Antifungal therapy in "bone marrow failure". British Journal of Haematology 1998;100:619-28. - PubMed
Ringdén 1991
    1. Ringdén O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E et al. Efficacy of amphothericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy 1991;28:73-82. - PubMed
Verfaillie 1991
    1. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplantation 1991;8:177-84. - PubMed
Walsh 1990
    1. Walsh TJ. Role of surveillance cultures in prevention and treatment of fungal infections. Journal of the National Cancer Institute. Monographs 1990;9:43-5. - PubMed
Walsh 2004
    1. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A. Caspofungin versus liposomal amphothericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. The New England Journal of Medicine 2004;351:1391-402. - PubMed

Publication types

MeSH terms